Cargando…
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
BACKGROUND: The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients. RESULTS: A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 compl...
Autores principales: | Sanz-Gallego, Irene, Rodriguez-de-Rivera, Francisco J, Pulido, Irene, Torres-Aleman, Ignacio, Arpa, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552149/ https://www.ncbi.nlm.nih.gov/pubmed/26331037 http://dx.doi.org/10.1186/s40673-014-0013-8 |
Ejemplares similares
-
IGF-1 in Friedreich’s Ataxia – proof-of-concept trial
por: Sanz-Gallego, Irene, et al.
Publicado: (2014) -
Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit
por: Pulido-Valdeolivas, Irene, et al.
Publicado: (2016) -
Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
por: Adanyeguh, Isaac M., et al.
Publicado: (2018) -
A heterozygous GRID2 mutation in autosomal dominant cerebellar ataxia
por: Koh, Kishin, et al.
Publicado: (2022) -
Autosomal recessive cerebellar ataxias
por: Palau, Francesc, et al.
Publicado: (2006)